Cargando…

Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking

The Ib-M6 peptide has antibacterial activity against non-pathogenic Escherichia coli K-12 strain. The first part of this study determines the antibacterial activity of Ib-M6 against fourteen pathogenic strains of E. coli O157:H7. Susceptibility assay showed that Ib-M6 had values of Minimum Inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Flórez-Castillo, J. M., Rondón-Villareal, P., Ropero-Vega, J. L., Mendoza-Espinel, S. Y., Moreno-Amézquita, J. A., Méndez-Jaimes, K. D., Farfán-García, A. E., Gómez-Rangel, S. Y., Gómez-Duarte, Oscar Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168133/
https://www.ncbi.nlm.nih.gov/pubmed/32059550
http://dx.doi.org/10.3390/antibiotics9020079
_version_ 1783523617524416512
author Flórez-Castillo, J. M.
Rondón-Villareal, P.
Ropero-Vega, J. L.
Mendoza-Espinel, S. Y.
Moreno-Amézquita, J. A.
Méndez-Jaimes, K. D.
Farfán-García, A. E.
Gómez-Rangel, S. Y.
Gómez-Duarte, Oscar Gilberto
author_facet Flórez-Castillo, J. M.
Rondón-Villareal, P.
Ropero-Vega, J. L.
Mendoza-Espinel, S. Y.
Moreno-Amézquita, J. A.
Méndez-Jaimes, K. D.
Farfán-García, A. E.
Gómez-Rangel, S. Y.
Gómez-Duarte, Oscar Gilberto
author_sort Flórez-Castillo, J. M.
collection PubMed
description The Ib-M6 peptide has antibacterial activity against non-pathogenic Escherichia coli K-12 strain. The first part of this study determines the antibacterial activity of Ib-M6 against fourteen pathogenic strains of E. coli O157:H7. Susceptibility assay showed that Ib-M6 had values of Minimum Inhibitory Concentration (MIC) lower than streptomycin, used as a reference antibiotic. Moreover, to predict the possible interaction between Ib-M6 and outer membrane components of E. coli, we used molecular docking simulations where FhuA protein and its complex with Lipopolysaccharide (LPS–FhuA) were used as targets of the peptide. FhuA/Ib-M6 complexes had energy values between −39.5 and −40.5 Rosetta Energy Units (REU) and only one hydrogen bond. In contrast, complexes between LPS–FhuA and Ib-M6 displayed energy values between −25.6 and −40.6 REU, and the presence of five possible hydrogen bonds. Hence, the antimicrobial activity of Ib-M6 peptide shown in the experimental assays could be caused by its interaction with the outer membrane of E. coli.
format Online
Article
Text
id pubmed-7168133
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71681332020-04-21 Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking Flórez-Castillo, J. M. Rondón-Villareal, P. Ropero-Vega, J. L. Mendoza-Espinel, S. Y. Moreno-Amézquita, J. A. Méndez-Jaimes, K. D. Farfán-García, A. E. Gómez-Rangel, S. Y. Gómez-Duarte, Oscar Gilberto Antibiotics (Basel) Article The Ib-M6 peptide has antibacterial activity against non-pathogenic Escherichia coli K-12 strain. The first part of this study determines the antibacterial activity of Ib-M6 against fourteen pathogenic strains of E. coli O157:H7. Susceptibility assay showed that Ib-M6 had values of Minimum Inhibitory Concentration (MIC) lower than streptomycin, used as a reference antibiotic. Moreover, to predict the possible interaction between Ib-M6 and outer membrane components of E. coli, we used molecular docking simulations where FhuA protein and its complex with Lipopolysaccharide (LPS–FhuA) were used as targets of the peptide. FhuA/Ib-M6 complexes had energy values between −39.5 and −40.5 Rosetta Energy Units (REU) and only one hydrogen bond. In contrast, complexes between LPS–FhuA and Ib-M6 displayed energy values between −25.6 and −40.6 REU, and the presence of five possible hydrogen bonds. Hence, the antimicrobial activity of Ib-M6 peptide shown in the experimental assays could be caused by its interaction with the outer membrane of E. coli. MDPI 2020-02-12 /pmc/articles/PMC7168133/ /pubmed/32059550 http://dx.doi.org/10.3390/antibiotics9020079 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Flórez-Castillo, J. M.
Rondón-Villareal, P.
Ropero-Vega, J. L.
Mendoza-Espinel, S. Y.
Moreno-Amézquita, J. A.
Méndez-Jaimes, K. D.
Farfán-García, A. E.
Gómez-Rangel, S. Y.
Gómez-Duarte, Oscar Gilberto
Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking
title Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking
title_full Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking
title_fullStr Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking
title_full_unstemmed Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking
title_short Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking
title_sort ib-m6 antimicrobial peptide: antibacterial activity against clinical isolates of escherichia coli and molecular docking
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168133/
https://www.ncbi.nlm.nih.gov/pubmed/32059550
http://dx.doi.org/10.3390/antibiotics9020079
work_keys_str_mv AT florezcastillojm ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking
AT rondonvillarealp ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking
AT roperovegajl ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking
AT mendozaespinelsy ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking
AT morenoamezquitaja ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking
AT mendezjaimeskd ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking
AT farfangarciaae ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking
AT gomezrangelsy ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking
AT gomezduarteoscargilberto ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking